SRSF3 and hnRNP H1 regulate a splicing hotspot of HER2 in breast cancer cells

References

• Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-12; http://dx.doi.org/10.1126/science.2470152
   PubMed Web of Science ®Google Scholar
• Bartsch R, Wenzel C, Steger GG. Trastuzumab in the management of early and advanced stage breast cancer. Biologics 2007; 1:19-31.
   PubMedGoogle Scholar
• Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-84; PMID:16236738; http://dx.doi.org/10.1056/NEJMoa052122
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719-26; PMID:11821453; http://dx.doi.org/10.1200/JCO.20.3.719
   PubMed Web of Science ®Google Scholar
• Dittrich A, Gautrey H, Browell D, Tyson-Capper A. The HER2 Signaling Network in Breast Cancer-Like a Spider in its Web. J Mammary Gland Biol Neoplasia 2014; 19(3–4):253-70; PMID:25544707
   PubMed Web of Science ®Google Scholar
• Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997; 16:1647-55; PMID:9130710; http://dx.doi.org/10.1093/emboj/16.7.1647
   PubMed Web of Science ®Google Scholar
• Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996; 16:5276-87; PMID:8816440
   PubMed Web of Science ®Google Scholar
• Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996; 15:2452-67; PMID:8665853
   PubMed Web of Science ®Google Scholar
• Jackson C, Browell D, Gautrey H, Tyson-Capper A. Clinical Significance of HER-2 Splice Variants in Breast Cancer Progression and Drug Resistance. Int J Cell Biol 2013; 2013:973584; PMID:23935627; http://dx.doi.org/10.1155/2013/973584
   PubMedGoogle Scholar
• Doherty JK, Bond C, Jardim A, Adelman JP, Clinton GM. The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc Natl Acad Sci U S A 1999; 96:10869-74; PMID:10485918; http://dx.doi.org/10.1073/pnas.96.19.10869
   PubMed Web of Science ®Google Scholar
• Aigner A, Juhl H, Malerczyk C, Tkybusch A, Benz C, Czubayko F. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation. Oncogene 2001; 20:2101-11; PMID:11360194; http://dx.doi.org/10.1038/sj.onc.1204305
   PubMed Web of Science ®Google Scholar
• Scott GK, Robles R, Park JW, Montgomery PA, Daniel J, Holmes WE, Lee J, Keller GA, Li WL, Fendly BM, et al. A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol 1993; 13:2247-57; PMID:8096058
   PubMed Web of Science ®Google Scholar
• Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 1999; 18:2149-64; PMID:10205169; http://dx.doi.org/10.1093/emboj/18.8.2149
   PubMed Web of Science ®Google Scholar
• Kwong KY, Hung MC. A novel splice variant of HER2 with increased transformation activity. Mol Carcinog 1998; 23:62-8; PMID:9808159; http://dx.doi.org/10.1002/(SICI)1098-2744(199810)23:2%3c62::AID-MC2%3e3.0.CO;2-O
   PubMed Web of Science ®Google Scholar
• Mitra D, Brumlik MJ, Okamgba SU, Zhu Y, Duplessis TT, Parvani JG, Lesko SM, Brogi E, Jones FE. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol Cancer Ther 2009; 8:2152-62; PMID:19671734; http://dx.doi.org/10.1158/1535-7163.MCT-09-0295
   PubMed Web of Science ®Google Scholar
• Castiglioni F, Tagliabue E, Campiglio M, Pupa SM, Balsari A, Menard S. Role of exon-16-deleted HER2 in breast carcinomas. Endocr Relat Cancer 2006; 13:221-32; PMID:16601290; http://dx.doi.org/10.1677/erc.1.01047
   PubMed Web of Science ®Google Scholar
• Marchini C, Gabrielli F, Iezzi M, Zenobi S, Montani M, Pietrella L, Kalogris C, Rossini A, Ciravolo V, Castagnoli L, et al. The human splice variant Delta16HER2 induces rapid tumor onset in a reporter transgenic mouse. PLoS One 2011; 6:e18727; PMID:21559085; http://dx.doi.org/10.1371/journal.pone.0018727
   PubMed Web of Science ®Google Scholar
• Alajati A, Sausgruber N, Aceto N, Duss S, Sarret S, Voshol H, Bonenfant D, Bentires-Alj M. Mammary tumor formation and metastasis evoked by a HER2 splice variant. Cancer Res 2013; 73:5320-7; PMID:23867476; http://dx.doi.org/10.1158/0008-5472.CAN-12-3186
   PubMed Web of Science ®Google Scholar
• Anido J, Scaltriti M, Bech Serra JJ, Santiago Josefat B, Todo FR, Baselga J, Arribas J. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J 2006; 25:3234-44; PMID:16794579; http://dx.doi.org/10.1038/sj.emboj.7601191
   PubMed Web of Science ®Google Scholar
• Pedersen K, Angelini PD, Laos S, Bach-Faig A, Cunningham MP, Ferrer-Ramon C, Luque-García A, García-Castillo J, Parra-Palau JL, Scaltriti M, et al. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol 2009; 29:3319-31; PMID:19364815; http://dx.doi.org/10.1128/MCB.01803-08
   PubMed Web of Science ®Google Scholar
• Ward TM, Iorns E, Liu X, Hoe N, Kim P, Singh S, Dean S, Jegg AM, Gallas M, Rodriguez C, et al. Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5. Oncogene 2013; 32:2463-74; PMID:22751112; http://dx.doi.org/10.1038/onc.2012.256
   PubMed Web of Science ®Google Scholar
• Michlewski G, Caceres JF. RNase-assisted RNA chromatography. RNA (New York, NY) 2010; 16:1673-8; http://dx.doi.org/10.1261/rna.2136010
   PubMed Web of Science ®Google Scholar
• Gautrey HL, Tyson-Capper AJ. Regulation of Mcl−1 by SRSF1 and SRSF5 in cancer cells. PLoS One 2012; 7:e51497; PMID:23284704; http://dx.doi.org/10.1371/journal.pone.0051497
   PubMed Web of Science ®Google Scholar
• Jia R, Li C, McCoy J, Deng C, Zheng Z. SRp20 is a proto-oncogene critical for cell proliferation and tumor induction and maintenance. Int J Biol Sci 2010; 6:806-26; PMID:21179588; http://dx.doi.org/10.7150/ijbs.6.806
   PubMed Web of Science ®Google Scholar
• He X, Arslan AD, Pool MD, Ho TT, Darcy KM, Coon JS, Beck WT. Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer. Oncogene 2011; 30:356-65; PMID:20856201; http://dx.doi.org/10.1038/onc.2010.426
   PubMed Web of Science ®Google Scholar
• Kurokawa K, Akaike Y, Masuda K, Kuwano Y, Nishida K, Yamagishi N, Kajita K, Tanahashi T, Rokutan K. Downregulation of serine/arginine-rich splicing factor 3 induces G1 cell cycle arrest and apoptosis in colon cancer cells. Oncogene 2014; 33:1407-17; PMID:23503458; http://dx.doi.org/10.1038/onc.2013.86
   PubMed Web of Science ®Google Scholar
• Tang Y, Horikawa I, Ajiro M, Robles AI, Fujita K, Mondal AM, Stauffer JK, Zheng ZM, Harris CC. Downregulation of splicing factor SRSF3 induces p53beta, an alternatively spliced isoform of p53 that promotes cellular senescence. Oncogene 2013; 32:2792-8; PMID:22777358; http://dx.doi.org/10.1038/onc.2012.288
   PubMed Web of Science ®Google Scholar
• Jang HN, Lee M, Loh TJ, Choi SW, Oh HK, Moon H, Cho S, Hong SE, Kim do H, Sheng Z, et al. Exon 9 skipping of apoptotic caspase-2 pre-mRNA is promoted by SRSF3 through interaction with exon 8. Biochim Biophys Acta 2014; 1839:25-32; PMID:24321384; http://dx.doi.org/10.1016/j.bbagrm.2013.11.006
   PubMed Web of Science ®Google Scholar
• Honore B, Baandrup U, Vorum H. Heterogeneous nuclear ribonucleoproteins F and H/H' show differential expression in normal and selected cancer tissues. Exp Cell Res 2004; 294:199-209; PMID:14980514; http://dx.doi.org/10.1016/j.yexcr.2003.11.011
   PubMed Web of Science ®Google Scholar
• Lefave CV, Squatrito M, Vorlova S, Rocco GL, Brennan CW, Holland EC, Pan YX, Cartegni L. Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. EMBO J 2011; 30:4084-97; PMID:21915099; http://dx.doi.org/10.1038/emboj.2011.259
   PubMed Web of Science ®Google Scholar
• Hope NR, Murray GI. The expression profile of RNA-binding proteins in primary and metastatic colorectal cancer: relationship of heterogeneous nuclear ribonucleoproteins with prognosis. Hum Pathol 2011; 42:393-402; PMID:21194727; http://dx.doi.org/10.1016/j.humpath.2010.08.006
   PubMed Web of Science ®Google Scholar
• Venables J, Koh C, Froehlich U, Lapointe E, Couture S, Inkel L, Bramard A, Paquet ER, Watier V, Durand M, et al. Multiple and specific mRNA processing targets for the major human hnRNP proteins. Mol Cell Biol 2008; 28:6033-43; PMID:18644864; http://dx.doi.org/10.1128/MCB.00726-08
   PubMed Web of Science ®Google Scholar
• Garneau D, Revil T, Fisette JF, Chabot B. Heterogeneous nuclear ribonucleoprotein F/H proteins modulate the alternative splicing of the apoptotic mediator Bcl−x. J Biol Chem 2005; 280:22641-50; PMID:15837790; http://dx.doi.org/10.1074/jbc.M501070200
   PubMed Web of Science ®Google Scholar
• Wang E, Aslanzadeh V, Papa F, Zhu H, de la Grange P, Cambi F. Global Profiling of Alternative Splicing Events and Gene Expression Regulated by hnRNPH/F. PLoS ONE 2012; 7:e51266.
   PubMed Web of Science ®Google Scholar
• Xiao X, Wang Z, Jang M, Nutiu R, Wang ET, Burge CB. Splice site strength-dependent activity and genetic buffering by poly-G runs. Nat Struct Mol Biol 2009; 16:1094-100; PMID:19749754; http://dx.doi.org/10.1038/nsmb.1661
   PubMed Web of Science ®Google Scholar
• Millevoi S, Decorsiere A, Loulergue C, Iacovoni J, Bernat S, Antoniou M, Vagner S. A physical and functional link between splicing factors promotes pre-mRNA 3′ end processing. Nucleic Acids Res 2009; 37:4672-83; PMID:19506027; http://dx.doi.org/10.1093/nar/gkp470
   PubMed Web of Science ®Google Scholar
• Millevoi S, Vagner S. Molecular mechanisms of eukaryotic pre-mRNA 3′ end processing regulation. Nucleic Acids Res 2010; 38:2757-74; PMID:20044349; http://dx.doi.org/10.1093/nar/gkp1176
   PubMed Web of Science ®Google Scholar
• Lou H, Neugebauer KM, Gagel RF, Berget SM. Regulation of alternative polyadenylation by U1 snRNPs and SRp20. Mol Cell Biol 1998; 18:4977-85; PMID:9710581
   PubMed Web of Science ®Google Scholar
• Huelga SC, Vu AQ, Arnold JD, Liang TY, Liu PP, Yan BY, Donohue JP, Shiue L, Hoon S, Brenner S, et al. Integrative genome-wide analysis reveals cooperative regulation of alternative splicing by hnRNP proteins. Cell Rep 2012; 1:167-78; PMID:22574288; http://dx.doi.org/10.1016/j.celrep.2012.02.001
   PubMed Web of Science ®Google Scholar